MX2010006984A - Vacunas contra la malaria. - Google Patents

Vacunas contra la malaria.

Info

Publication number
MX2010006984A
MX2010006984A MX2010006984A MX2010006984A MX2010006984A MX 2010006984 A MX2010006984 A MX 2010006984A MX 2010006984 A MX2010006984 A MX 2010006984A MX 2010006984 A MX2010006984 A MX 2010006984A MX 2010006984 A MX2010006984 A MX 2010006984A
Authority
MX
Mexico
Prior art keywords
antigen
component
rts
immunogenic particle
stabilizing agent
Prior art date
Application number
MX2010006984A
Other languages
English (en)
Inventor
Dominique Ingrid Lemoine
Florence Emilie Jeanne Francoise Wauters
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40584700&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010006984(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MX2010006984A publication Critical patent/MX2010006984A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención se refiere a un componente para una vacuna contra la malaria que comprende: a) una partícula inmunógena RTS,S y/o b) una partícula inmunógena que se deriva de la proteína CS de una o más cepas de P. vivax y el antígeno S de la Hepatitis 8 y opcionalmente el antígeno s sin fusionar, o c) una partícula inmunógena que comprende RTS, CSV-S y opcionalmente el antígeno S sin fusionar, y d) un agente estabilizante que comprende un agente estabilizante con al menos un grupo funcional tiol, o sus mezclas. También se describen procedimientos para preparar el componente, su uso en medicina, en particular en la prevención de infecciones de malaria, composiciones/vacunas que contienen el componente y su uso, en particular en terapia.
MX2010006984A 2007-12-21 2008-12-18 Vacunas contra la malaria. MX2010006984A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1576207P 2007-12-21 2007-12-21
PCT/EP2008/067925 WO2009080715A2 (en) 2007-12-21 2008-12-18 Vaccines for malaria

Publications (1)

Publication Number Publication Date
MX2010006984A true MX2010006984A (es) 2010-10-25

Family

ID=40584700

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006984A MX2010006984A (es) 2007-12-21 2008-12-18 Vacunas contra la malaria.

Country Status (22)

Country Link
US (1) US20100272745A1 (es)
EP (1) EP2234637A2 (es)
JP (1) JP2011507816A (es)
KR (1) KR20100109556A (es)
CN (1) CN102026657A (es)
AP (1) AP2010005296A0 (es)
AR (1) AR071741A1 (es)
AU (1) AU2008339980A1 (es)
BR (1) BRPI0822098A2 (es)
CA (1) CA2708716A1 (es)
CL (1) CL2008003808A1 (es)
CO (1) CO6300963A2 (es)
CR (1) CR11577A (es)
DO (1) DOP2010000189A (es)
IL (1) IL206308A0 (es)
MA (1) MA32030B1 (es)
MX (1) MX2010006984A (es)
PE (1) PE20091528A1 (es)
TW (1) TW200940086A (es)
UY (1) UY31569A1 (es)
WO (1) WO2009080715A2 (es)
ZA (1) ZA201004304B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013142278A1 (en) * 2012-03-22 2013-09-26 New York University Plasmodium vivax vaccine compositions
WO2016184784A1 (en) 2015-05-15 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Peptides including binding domain of plasmodium falciparum proteins (cbp1 and cbp2) to chemokine cx3cl1
SG10202012205XA (en) 2015-11-06 2021-01-28 Adjuvance Technologies Inc Triterpene saponin analogues
CN105233296B (zh) * 2015-11-24 2018-08-17 江苏省农业科学院 用于鸭病毒性肝炎活疫苗的耐热冻干保护剂及其制备方法和应用
GB201608821D0 (en) * 2016-05-19 2016-07-06 Isis Innovation Vaccines
AU2018258070A1 (en) * 2017-04-25 2019-10-24 Adjuvance Technologies, Inc. Triterpene saponin analogues
JP7177082B2 (ja) * 2017-04-25 2022-11-22 アジュバンス・テクノロジーズ・インコーポレーテッド トリテルペンサポニン類似物
JP2020536946A (ja) 2017-10-16 2020-12-17 アジュバンス・テクノロジーズ・インコーポレーテッド トリテルペンサポニン類似物
US20220177558A1 (en) 2019-03-25 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of taupathy disorders by targeting new tau species

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819209D0 (en) * 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
CA2075521C (en) * 1992-05-05 1995-11-28 Kuniaki Koyama Stabilized live vaccine
ZA973642B (en) * 1996-04-26 1997-11-25 Merck & Co Inc DNA vaccine formulations.
AU727306B2 (en) * 1996-04-26 2000-12-07 Merck Sharp & Dohme Corp. DNA vaccine formulations
GB9616351D0 (en) * 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
EP1009382B1 (en) * 1997-09-05 2003-06-18 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
JP2003500456A (ja) * 1999-06-02 2003-01-07 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド 角質細胞増殖因子−２製剤
CA2546195A1 (en) * 2003-11-21 2005-06-02 Pfizer Products Inc. The use of anti biotics as vaccine adjuvants
SG183683A1 (en) * 2004-02-02 2012-09-27 Tanox Inc Identification of novel ige epitopes
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
WO2007079351A2 (en) * 2005-12-15 2007-07-12 Aeras Global Tb Vaccine Foundation Novel prime-boost combinations of attenuated mycobacterium
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions

Also Published As

Publication number Publication date
MA32030B1 (fr) 2011-01-03
CR11577A (es) 2010-09-03
CA2708716A1 (en) 2009-07-02
DOP2010000189A (es) 2010-08-15
TW200940086A (en) 2009-10-01
WO2009080715A2 (en) 2009-07-02
CN102026657A (zh) 2011-04-20
WO2009080715A3 (en) 2009-11-12
IL206308A0 (en) 2010-12-30
JP2011507816A (ja) 2011-03-10
ZA201004304B (en) 2012-11-28
PE20091528A1 (es) 2009-10-29
KR20100109556A (ko) 2010-10-08
UY31569A1 (es) 2009-08-03
EP2234637A2 (en) 2010-10-06
BRPI0822098A2 (pt) 2015-06-30
CL2008003808A1 (es) 2011-03-11
AP2010005296A0 (en) 2010-06-30
AR071741A1 (es) 2010-07-14
CO6300963A2 (es) 2011-07-21
AU2008339980A1 (en) 2009-07-02
US20100272745A1 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
MX2010006984A (es) Vacunas contra la malaria.
MX2009000655A (es) Vacunasd para malaria.
WO2006113214A3 (en) Vaccine against pandemic strains of influenza viruses
BR112018009032A8 (pt) vetor viral de arenavírus infeccioso, composição farmacêutica, composição imunogênica, vacina, método para o tratamento ou a prevenção de infecção pelo vírus da hepatite b em um paciente, uso de um vetor viral, ácido nucleico isolado, vetor viral de arenavírus infeccioso deficiente em replicação e método para sua geração
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
WO2007002470A3 (en) Inactivated chimeric vaccines and related methods of use
MX2018010586A (es) Nanovacuna de activacion de "sting" para inmunoterapia.
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
HK1207828A1 (en) Cell-derived viral vaccines with low levels of residual cell dna dna
WO2007024941A3 (en) Polyvalent vaccine
IL164812A0 (en) Packaged virus-like particles for use as adjuvants: method of preparation and use
MX2008016036A (es) Vacuna viral recombinante.
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
WO2006115843A3 (en) Nipah virus vaccines
PH12015501637A1 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
MX2022000718A (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9.
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
NZ596223A (en) Combined measles-malaria vaccine
MX2011006516A (es) Terapia de combinacion de virus de hepatitis c.
UY31574A1 (es) Vacunas contra la malaria
NZ591738A (en) Non-typhoidal salmonella vaccines comprising a polypeptide which is an outer membrane protein d of non typoidal salmonella
TN2014000393A1 (en) Modified marek's disease virus, and vaccines made therefrom
WO2012027473A3 (en) Immunogenic compositions comprising alphavirus vectored dengue virus e protein antigens
UA95293C2 (en) Vaccines for malaria

Legal Events

Date Code Title Description
FA Abandonment or withdrawal